An HL60-Fc fusion protein, its preparation method and application

By constructing the HL60-Fc fusion protein, which combines tumor-targeting cell-penetrating peptides and Fc fragments, the drug resistance problem of ICB therapy in tumors such as colorectal cancer, pancreatic cancer, and lung cancer has been solved, achieving highly efficient anti-tumor immune activation and tumor targeting, and providing a new tumor immunotherapy strategy.

CN123106919APending Publication Date: 2026-11-17SUN YAT SEN UNIVERSITY CANCER CENTER (CANCER HOSPITAL AFFILIATED TO SUN YAT SEN UNIVERSITY CANCER RESEARCH INSTITUTE OF SUN YAT SEN UNIVERSITY)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611010061.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-07-08
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing ICB therapies suffer from resistance in tumors such as colorectal cancer, pancreatic cancer, and lung cancer. The natural DDX60 protein has a short half-life and insufficient tumor targeting, making it difficult to effectively enter tumor cells and exert its function.

Method used

We constructed an HL60-Fc fusion protein that combines tumor-targeting cell-penetrating peptides, the DDX60 functional domain, and Fc fragments of IgG antibody types. This protein synergistically enhances anti-tumor immunity through HL60-mediated intracellular pathogen pattern recognition and Fc-mediated immune cell recruitment/activation.

Benefits of technology

It enhances the sensitivity of tumors to immune checkpoint inhibitors, improves the efficacy of anti-tumor immunotherapy, overcomes the problem of tumor drug resistance, and has tumor targeting and highly efficient immune activation capabilities.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This invention belongs to the field of biomedical technology and discloses an HL60-Fc fusion protein, its preparation method, and its applications. This invention provides a fusion protein with tumor-targeting cell penetration and anti-tumor immune activation functions. This fusion protein can directly deliver the DDX60 functional domain into tumor cells and maintain the stability of dsRNA; simultaneously, it can enhance the sensitivity of other anti-tumor immunotherapies by activating the body's own immunity. The fusion protein can serve as a novel natural immune agonist, synergistically enhancing anti-tumor immunity through a dual mechanism (HL60-mediated intracellular pathogen pattern recognition and Fc-mediated immune cell recruitment / activation). It is expected to overcome the drug resistance problem of existing ICB therapies in "cold tumors" such as colorectal cancer, pancreatic cancer, and lung cancer, providing a new and effective strategy for tumor immunotherapy and holding significant importance in tumor treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedical technology, specifically relating to an HL60-Fc fusion protein, its preparation method, and its application. Background Technology

[0002] Immune checkpoint blockade (ICB) therapy has been approved for the clinical treatment of various tumor types and has shown some success in solid tumors such as melanoma and lung cancer, improving patient prognosis. However, in colorectal cancer (CRC), only a portion of patients with high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) show a treatment response, while more than 80% of CRC patients are microsatellite stable (MSS) or mismatch repair normal (pMMR) subtypes and cannot benefit from ICB treatment. Furthermore, most patients with pancreatic, gastric, and lung cancers are resistant to ICB treatment regimens. Therefore, developing new immunotherapy strategies and combination therapies is of great significance for improving the treatment efficacy and survival rates of patients with colorectal, pancreatic, gastric, and lung cancers.

[0003] Innate immune responses play a crucial role in activating T-cell immunity and promoting tumor cell antigen presentation. Among these responses, the DDX60 protein (a member of the RNA helicase family whose expression is downregulated in various tumors) has been shown to enhance the immunogenicity of tumor cells and promote CD8 expression by recognizing abnormal intracellular nucleic acid structures and initiating the downstream interferon (IFN) signaling pathway. + T-cell infiltration. Studies have shown that the expression level of DDX60 protein in tumor tissues such as colorectal cancer, lung cancer, and pancreatic cancer is significantly lower than that in adjacent normal tissues, and its expression level is positively correlated with the patient's response to ICB therapy. However, the short half-life of natural DDX60 protein in vivo, insufficient tumor targeting, and difficulty in effectively entering tumor cells to exert its function limit its direct application as a protein drug.

[0004] To overcome the aforementioned limitations, the applicant previously constructed an HL60 fusion protein (fusing HL60 with a cell-penetrating peptide), achieving initial delivery into tumor cells and observing certain anti-tumor activity. However, this fusion protein still suffers from problems such as a short in vivo half-life and limited immune activation efficiency. Summary of the Invention

[0005] This invention aims to address at least one of the technical problems existing in the prior art. The invention introduces an immunoglobulin Fc fragment into the HL60 fusion protein to construct the HL60-Fc fusion protein. This fusion protein can serve as a novel natural immune agonist, synergistically enhancing anti-tumor immunity through a dual mechanism (HL60-mediated intracellular pathogen pattern recognition and Fc-mediated immune cell recruitment / activation). It is expected to overcome the drug resistance problem of existing ICB therapies in "cold tumors" such as colorectal cancer, pancreatic cancer, and lung cancer, providing a new and effective strategy for tumor immunotherapy.

[0006] The first aspect of the present invention is to provide a fusion protein.

[0007] The second aspect of the present invention aims to provide biomaterials related to the fusion protein of the first aspect of the present invention.

[0008] The third aspect of this invention aims to provide the application of the fusion protein of the first aspect of this invention or the biomaterial of the second aspect of this invention.

[0009] The fourth aspect of this invention is to provide a drug.

[0010] To achieve the above objectives, the technical solution adopted by the present invention is as follows: DDX60 is a crucial factor in maintaining the body's anti-tumor immunity. The choice of a fusion protein approach to supplement DDX60 in tumor cells is due to the significant advantages of protein drugs compared to small molecule drugs, including high activity, strong specificity, low toxicity, well-defined biological functions, and ease of production through prokaryotic or eukaryotic expression, which facilitates large-scale production and clinical application. Based on the mechanism of action and structural characteristics of DDX60, this application constructs a protein drug system, HL60-Fc, that induces the release of tumor-associated immune factors using a fusion expression method. A series of functional experiments were then used to verify the effectiveness of HL60-Fc in activating anti-tumor immunity.

[0011] In a first aspect, the present invention provides a fusion protein comprising a tumor-targeting cell-penetrating peptide, a DDX60 functional domain, and an Fc fragment of an IgG antibody. The nucleotide sequence of the Fc fragment is as shown in SEQ ID NO:9, or the amino acid sequence shown in SEQ ID NO:9 after substitution, deletion or addition of one or more amino acids and with the same or similar function.

[0012] In some embodiments of the present invention, the tumor-targeting cell-penetrating peptide includes BR2.

[0013] In some embodiments of the present invention, the amino acid sequence of the tumor-targeting cell-penetrating peptide is as shown in SEQ ID NO:3, or the amino acid sequence shown in SEQ ID NO:3 is modified by substitution, deletion or addition of one or more amino acids and has the same or similar function.

[0014] In some embodiments of the present invention, the tumor includes at least one of colorectal cancer, bladder cancer, breast cancer, cervical squamous cell carcinoma, pheochromocytoma, diffuse large B-cell lymphoma, esophageal cancer, glioblastoma, head and neck tumor, kidney cancer, acute myeloid leukemia, glioma, liver cancer, lung cancer, pancreatic cancer, nasopharyngeal carcinoma, kidney cancer, lung cancer, liver cancer, breast cancer, prostate cancer, gastrointestinal cancer, sarcomatoid lung cancer, gastric adenocarcinoma, thyroid cancer, and thymic carcinoma.

[0015] In some embodiments of the present invention, the DDX60 functional domain includes an ATP-binding and hydrolysis domain and an RNA-binding domain, wherein the ATP-binding and hydrolysis domain and the RNA-binding domain are linked by a flexible linker.

[0016] In some embodiments of the present invention, the amino acid sequence of the ATP-binding and hydrolysis domain is any one of a1) to a3): a1) As shown in SEQ ID NO:7; a2) SEQ ID NO:7 is an amino acid sequence that has undergone substitution and / or deletion and / or addition of one or more amino acids and has the same or similar function; a3) An amino acid sequence that has 99%, 98%, 97%, 96%, 95%, 94%, 93% or 92% homology with SEQ ID NO:7 and has the same function as SEQ ID NO:7.

[0017] In some embodiments of the present invention, the amino acid sequence of the RNA-binding domain is any one of b1) to b3): b1) As shown in SEQ ID NO:8; b2) The amino acid sequence of SEQ ID NO:8 that has undergone substitution and / or deletion and / or addition of one or more amino acids and has the same or similar function; b3) An amino acid sequence that has 99%, 98%, 97%, 96%, 95%, 94%, 93% or 92% homology with SEQ ID NO:8 and has the same function as SEQ ID NO:8.

[0018] In some embodiments of the present invention, the ATP binding and hydrolysis domain is located at the N-terminus or C-terminus of the RNA binding domain; preferably at the N-terminus.

[0019] In some embodiments of the present invention, the amino acid sequence of the DDX60 functional domain is shown in SEQ ID NO:6.

[0020] In some embodiments of the present invention, the tumor-targeting cell-penetrating peptide, the DDX60 functional domain, and the Fc fragment are linked by a flexible linker.

[0021] In some embodiments of the present invention, the amino acid sequence of the flexible linker is (GGCAGCGCCAGC). n (GGCGGCGGCAGC) n (GGCGGCGGCGGCAGC) n YAPVDV, (GGGS) n (GGSG) n (GSG) n GGGSSGG, (GGGGS) n , where 1≤n≤10, and n is an integer.

[0022] In some embodiments of the present invention, the DDX60 functional domain is located at the N-terminus or C-terminus of the tumor-targeting cell-penetrating peptide; preferably at the C-terminus.

[0023] In some embodiments of the present invention, the Fc segment is located at the N-terminus or C-terminus of the DDX60 functional structure domain; preferably at the C-terminus.

[0024] In some embodiments of the present invention, the fusion protein further comprises other functional groups.

[0025] In some embodiments of the present invention, the functional group includes at least one of a reporter group, a protein tag, a carrier, and a lipid group.

[0026] In this invention, the position of the functional group is not limited. Based on actual usage requirements and the specific selection of the functional group, it can be optionally inserted at any position at both ends or in the middle of the fusion protein, while significantly reducing at least one function of the fusion protein. In this invention, the function includes immunogenicity.

[0027] In some embodiments of the present invention, the protein tags include, but are not limited to: affinity tags, such as GST, His, MBP, etc.; epitope tags, such as HA, Myc, Flag, etc.; fluorescent tags, such as GFP, mCherry, etc.; and other tags, such as SNAP and Avi, etc.

[0028] In some embodiments of the present invention, the carrier includes, but is not limited to, carrier proteins, such as hemocyanin, serum albumin, ovalbumin, etc.

[0029] In some embodiments of the present invention, the lipid groups include, but are not limited to, fatty acid chains (such as palmitic acid) to form lipopeptides.

[0030] In some embodiments of the present invention, the amino acid sequence of the fusion protein is as shown in SEQ ID NO:2; or the amino acid sequence shown in SEQ ID NO:2 is modified by substitution, deletion or addition of one or more amino acids and has the same or similar function.

[0031] A second aspect of the invention provides biomaterials related to the fusion protein of the first aspect of the invention, said biomaterials being any one of c1) to c12): c1) A nucleic acid molecule encoding the fusion protein of the first aspect of the present invention; c2) An expression cassette containing the nucleic acid molecule described in c1); c3) A recombinant vector containing the nucleic acid molecule described in c1); c4) A recombinant vector containing the expression cassette described in c2); c5) Recombinant microorganisms containing the nucleic acid molecules described in c1); c6) Recombinant microorganisms containing the expression cassette described in c2); c7) Recombinant microorganisms containing the recombinant vector described in c3); c8) Recombinant microorganisms containing the recombinant vector described in c4); c9) Transgenic animal cell lines containing the nucleic acid molecules described in c1); c10) Transgenic animal cell lines containing the expression cassette described in c2); c11) Transgenic animal cell lines containing the recombinant vector described in c3); c12) Transgenic animal cell lines containing the recombinant vector described in c4); The transgenic animal cell lines do not contain reproductive material.

[0032] In some embodiments of the present invention, the vector is independently selected from non-pathogenic viral vectors and viral vectors.

[0033] In some embodiments of the present invention, the viral vector includes at least one of lentiviral vector, adenovirus vector, baculovirus vector, retrovirus vector, poxvirus vector, Sendai virus vector, and herpes simplex virus vector.

[0034] In some embodiments of the present invention, the non-viral vector includes at least one of plasmid vectors, cationic polymer vectors, chitosan, polyethyleneimine, nanoparticle vectors, and liposomes.

[0035] In some embodiments of the present invention, the vector is a plasmid vector, a phage particle, a viral vector, a cell vector, a bacteriophage, a sclerotium, an F sclerotium, or an artificial chromosome.

[0036] In some embodiments of the present invention, the plasmid vector may be an optional plasmid, and the viral vector may be an optional virus.

[0037] In some embodiments of the present invention, the cells include prokaryotic cells and eukaryotic cells; the cells are not new plant or animal varieties.

[0038] In some embodiments of the present invention, the prokaryotic cells include bacteria well known in the art, such as Escherichia coli, Streptomyces, and Bacillus subtilis, which are capable of expressing the target protein.

[0039] In some embodiments of the present invention, the eukaryotic cells include at least one of yeast cells, mammalian cells (such as 293 cells, 293T cells or 293F cells), plant cells and insect cells.

[0040] In some embodiments of the present invention, the cells are immune cells, such as T cells, B cells, NK cells, iNKT cells, CTL cells, dendritic cells, myeloid cells, monocytes, macrophages, or any combination thereof.

[0041] In some embodiments of the present invention, the nucleotide sequence of the nucleic acid molecule is shown in SEQ ID NO:1.

[0042] A third aspect of the invention provides the use of the fusion protein of the first aspect of the invention or the biomaterial of the second aspect of the invention in any one of d1)-d3): d1) Preparation of drugs for the prevention and / or treatment of tumors; d2) Preparation of drugs that activate anti-tumor immunity; d3) Prepare drugs that enhance the anti-tumor effects of immune checkpoint inhibitors.

[0043] In some embodiments of the present invention, the tumor includes at least one of colorectal cancer, bladder cancer, breast cancer, cervical squamous cell carcinoma, pheochromocytoma, diffuse large B-cell lymphoma, esophageal cancer, glioblastoma, head and neck tumor, kidney cancer, acute myeloid leukemia, glioma, liver cancer, lung cancer, pancreatic cancer, nasopharyngeal carcinoma, kidney cancer, lung cancer, liver cancer, breast cancer, prostate cancer, gastrointestinal cancer, sarcomatoid lung cancer, gastric adenocarcinoma, thyroid cancer, and thymic carcinoma.

[0044] In some embodiments of the present invention, the drug described in d3) enhances the anti-tumor effect of immune checkpoint inhibitors by increasing the sensitivity of tumors to immune checkpoint inhibitors.

[0045] In some embodiments of the present invention, the immune checkpoint inhibitor is an inhibitor that acts on T cell negative co-stimulatory (co-inhibitory) molecules and / or their respective ligands.

[0046] In some embodiments of the present invention, the molecules acting on negative co-stimulatory (co-inhibitory) T cells and / or their respective ligands are selected from CTLA-4 (e.g., ipilimumab, ticilimumab; CP-675, 206, AGEN-1884, ATOR-1015, MGD019 (PD-1 / CTLA-4 bispecific antibody)) and PD-1 (e.g., nivolumab, pembrolizumab). embrolizumab, tremelimumab, tislelizumab (BGB-A317), spartalizumab, MEDI0680, PDR001, FAZ053, MGA012 (retifanlimab), sintilimab, toripalimab, cemiplimab, MGD019 (PD-1 / CTLA-4 bispecific antibody), MGD013 (tebotelimab (PD-1 / LAG-3 bispecific antibody)), PD-L1 inhibitors (e.g., atezolizumab, camrelizumab, durvalumab, avelumab), LY3300054, CX-072 (Proclaim-CX-072) FAZ053, KN035, MDX-1105), PD-L2, B7-1, B7-2, B7-H3 (e.g., enoblituzumab, MGD009, MGC018), B7-H4, B7-H6, A2aR (e.g., CPI-444, PBF509), IDO (e.g., GDC0919 (navoximod), epacadostat, indoximid, BMS) 986205), TIM-3 (e.g., TSR022 (TIM-3 monoclonal antibody), MBG453 (TIM-3 monoclonal antibody)), BTLA, VISTA, TIGIT (e.g., BMS-986207, AB154, COM902 (CGEN-15137), OMP-313M32), LAG-3 (e.g., BMS986016, MK-4280 (28G-10), REGN3767, GSK2831781, IMP731 (H5L7BW), BAP050, IMP-701 (LAG-5250), IMP321, TSR-033, LAG525, BI754111, FS-118, MGD013 (tebotelimab,PD-1 / LAG-3 bispecific antibodies), CD40 (e.g., BMS3h-56, lucatumumab (HCD122 and CHIR-12.12), CHIR-5.9 or dacetuzumab), CD20 (e.g., rituximab (RITUXAN; IDEC-102; IDEC-C2B8), ABP798, ofatumumab or obinutuzumab), CD96, CD73 (e.g., MEDI9447 (oleclumab), CD160 (e.g., BY55), STING, CEA (e.g., cergutuzumab) amunaleukin (RG7813, RO-6895882 or RG7802 (RO6958688)), CD47 (e.g., HuF9-G4, CC-90002, TTI-621, ALX148, NI-1701, NI-1801, SRF231 or Effi-DEM), PVRIG antibodies (e.g., COM701 (CGEN-15029)), LAIR1, 2B4, KIR (e.g., liri Lumbab (1-7F9, BMS-986015, IPH2101, IPH4102), CEACAM1 (e.g., CM-24 (MK-6018)), GARP (e.g., ARGX-115), PS, CSF1R (e.g., pexidartinib, LY3022855, FPA008, BLZ945), CD94 / NKG2A, TDO, TNFR, and DCR3 are one or more of these.

[0047] In some embodiments, the inhibitors acting on T cell negative costimulatory (co-inhibitory) molecules and / or their respective ligands comprise any one of (b1)-(b3): ​​(b1) antibodies that specifically bind (neutralize) T cell negative costimulatory (co-inhibitory) molecules and / or their respective ligands; (b2) ligand proteins or peptides that specifically bind (neutralize) T cell negative costimulatory (co-inhibitory) molecules and / or their respective ligands; and (b3) non-protein compounds that specifically bind (neutralize) T cell negative costimulatory (co-inhibitory) molecules and / or their respective ligands.

[0048] In a fourth aspect, the present invention provides a medicament comprising a fusion protein of the first aspect of the present invention or a biomaterial of the second aspect of the present invention.

[0049] In some embodiments of the present invention, the drug further includes pharmaceutically acceptable excipients.

[0050] In some embodiments of the present invention, the pharmaceutically acceptable excipients include at least one of diluents, wetting agents, binders, disintegrants, lubricants, flavor and color modifiers, solvents, solubilizers, cosolvents, emulsifiers, absorption enhancers, surfactants, antioxidants, excipients, stabilizers, flavoring agents, sustained-release agents, metal complexing agents, inert gases, preservatives, fillers, local analgesics, pH adjusters, and isotonic or isotropic modifiers.

[0051] In some embodiments of the present invention, the diluent includes, but is not limited to, at least one of starches, sugars, celluloses, and inorganic salts. The wetting agent includes, but is not limited to, at least one of water, ethanol, and propanol. The binder includes, but is not limited to, at least one of starch paste, dextrin, sugar, cellulose derivatives, gelatin, povidone, and polyethylene glycol. The disintegrant includes, but is not limited to, at least one of microcrystalline cellulose, croscarmellose, croscarmellose sodium starch, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, croscarmellose sodium, croscarmellose, surfactants (such as sodium dodecylbenzenesulfonate, stearic acid, polyoxyethylene-polyoxypropylene copolymer, fatty acid sorbitan, or polysorbate, etc.), and effervescent disintegrants. The lubricant includes, but is not limited to, at least one of talc, calcium stearate, magnesium stearate, magnesium dodecyl sulfate, micronized silica gel, calcium carbonate, sodium bicarbonate, and polyethylene glycol. The color, flavor, and aroma modifiers include, but are not limited to, at least one of pigments, fragrances, sweeteners, adhesives, and odorants. The solvents include, but are not limited to, at least one of the following: water, ethanol, glycerol, propylene glycol, polyethylene glycol, dimethyl sulfoxide, liquid paraffin, fatty oil, ethyl acetate, and vegetable oils (such as soybean oil, castor oil, peanut oil, blended oil, etc.). The solubilizers include, but are not limited to, at least one of the following: Tween derivatives, methyl ethers, polyoxyethylene fatty alcohol ethers, soaps, sulfates, and sulfonates. The co-solvents include, but are not limited to, at least one of the following: organic acids and their salts, amides and amines, inorganic salts, polyethylene glycol, povidone, and glycerol. The emulsifiers include, but are not limited to, at least one of the following: Span derivatives, Tween derivatives, methyl ethers, benzyl ethers, glyceryl fatty acid esters, higher fatty acid salts, sulfates, sulfonates, gum arabic, tragacanth gum, gelatin, pectin, phospholipids, agar, sodium alginate, hydroxides, silica, and bentonite. The suspending agent includes, but is not limited to, at least one of the following: glycerin, syrup, gum arabic, tragacanth gum, agar, sodium alginate, cellulose derivatives, povidone, carbomer, polyvinyl alcohol, and thixotropic gum. The antioxidants include, but are not limited to, at least one of the following: sulfites, metabisulfites, bisulfites, ascorbic acid, gallic acid, and their esters. The metal complexing agent includes, but is not limited to, at least one of the following: disodium EDTA and polycarboxylic acid compounds. The inert gas includes, but is not limited to, at least one of the following: nitrogen and carbon dioxide. The preservatives include, but are not limited to, at least one of the following: parabens, organic acids and their salts, quaternary ammonium compounds, chlorhexidine acetate, alcohols, phenols, and volatile oils. The filler includes, but is not limited to, at least one of the following: starch, sucrose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, or glucose. The flavoring agent includes, at least one of the following: aspartame, sucralose, flavoring, stevia, acesulfame potassium, citric acid, or sodium saccharin. The local analgesics include, but are not limited to, at least one of benzyl alcohol, chlorobutanol, lidocaine, and procaine.The pH adjuster includes, but is not limited to, at least one of the following: hydrochloric acid, sulfuric acid, phosphoric acid, citric acid, tartaric acid, acetic acid, sodium hydroxide, sodium bicarbonate, ethylenediamine, meglumine, phosphate, acetate, and citrate. The isotonic or isotropic adjuster includes, but is not limited to, at least one of the following: glucose, sodium chloride, sodium citrate, sorbitol, and xylitol.

[0052] In some embodiments of the present invention, the medicament further includes a combination drug, which includes an oncology-targeting drug. In this case, at least two active ingredients may be administered together or separately, as part of the same pharmaceutical formulation or as different formulations.

[0053] In some embodiments of the present invention, the drug further includes combination drugs, including antitumor drugs.

[0054] In some embodiments of the present invention, the antitumor drug is selected from at least one of chemotherapy drugs, radiotherapy drugs, photosensitizers, photothermal agents, immunotherapy drugs, or drugs that relieve immunosuppression.

[0055] In some embodiments of the present invention, the chemotherapeutic agent is selected from at least one of alkylating agents, platinum-based drugs, podophyllotoxins, camptothecin-based drugs, taxanes, anthracyclines, fluoropyrimidines, or antibiotics.

[0056] In some embodiments of the present invention, the chemotherapeutic agent comprises (a) alkylating agents, such as nitrogen mustard (e.g., nitrogen mustard, cyclophosphamide, ifosfamide, melphalan, chlorambucil), ethyleneimine and methylmelamine (e.g., hexamethylmelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomustine, chlorurea, streptozotocin), and triazines (e.g., dacarbazine); (b) antimetabolites, such as folic acid analogs (e.g., methotrexate), pyrimidine analogs (e.g., gemcitabine, capecitabine, 5-fluorouracil, fluorouracil, cytarabine, aziridine), and purine analogs and related substances (e.g., 6-mercaptopurine). (c) Natural products, such as vinca alkaloids (e.g., vincristine, vinblastine), epipodophyllotoxin (e.g., etoposide, teniposide), antibiotics (e.g., actinomycin D, daunorubicin, doxorubicin, mitomycin, epirubicin, bleomycin, pricamycin, and mitoxantrone), enzymes (e.g., L-asparaginase), biological response modifiers (e.g., interferon-α); (d) Other reagents, such as at least one of platinum coordination complexes (e.g., cisplatin, carboplatin), substituted ureas (e.g., hydroxyurea), methylhydrazine derivatives (e.g., procarbazine), and adrenocortical inhibitors (e.g., paclitaxel and mitotane).

[0057] In some embodiments of the present invention, the chemotherapeutic agent includes at least one of gemcitabine, oxaliplatin, paclitaxel, camptothecin, 5-fluorouracil, cisplatin, doxorubicin, mitomycin, or epirubicin.

[0058] In some embodiments of the present invention, the radiotherapy drug is selected from at least one of the drugs used in external radiotherapy, internal radiotherapy, radioimmunotherapy, or intraoperative radiotherapy (IORT).

[0059] In some embodiments of the present invention, the photosensitizer is selected from at least one of dipyrrole, dihydroporphyrin, or Bengal red.

[0060] In some embodiments of the present invention, the photothermal agent is selected from at least one of noble metal nanoparticles, organic polymers, carbon-based nanomaterials, magnetic nanomaterials, or semiconductor nanomaterials.

[0061] In some embodiments of the present invention, the immunotherapeutic drug comprises at least one of monoclonal antibodies, immune checkpoint inhibitors, immune cells, oncolytic viruses, and tumor vaccines.

[0062] In some embodiments of the present invention, the drug is administered to an animal; more preferably, the animal is a mammal; even more preferably, the animal is selected from humans, cats, cattle, sheep, pigs, dogs, chickens, ducks, geese, rabbits, and mice; and even more preferably, the animal is a human, including minors, adults, and the elderly.

[0063] In some embodiments of the present invention, the dosage form of the drug includes a gastrointestinal dosage form or a non-gastrointestinal dosage form.

[0064] In some embodiments of the present invention, the gastrointestinal dosage form includes at least one of powder, tablet, granule, capsule, sustained-release, solution, dry suspension, effervescent tablet, emulsion, suspension, syrup, drops, and chewable tablet.

[0065] In some embodiments of the present invention, the gastrointestinal dosage forms include, but are not limited to, enteric-coated tablets, coated tablets, film-coated tablets, sugar-coated tablets, dispersible tablets, sucking tablets, chewable tablets, effervescent tablets, scratch tablets, sustained-release and controlled-release dosage forms, sustained-release tablets, sustained-release coated tablets, controlled-release tablets, orally disintegrating tablets, lozenges, and oral patches.

[0066] In some embodiments of the present invention, the non-gastrointestinal drug delivery dosage form includes at least one of injection dosage form, respiratory dosage form, skin dosage form, mucosal dosage form, and cavity dosage form.

[0067] In some embodiments of the present invention, the injectable dosage forms include, but are not limited to, injection solutions, solutions for injection, injection solutions for intravenous infusion, suspensions for injection, sterile powders for injection, intravenous injections, water injections, emulsions for injection, powder injections, injections, sterile powder injections, lyophilized powder injections, etc.

[0068] In some embodiments of the present invention, the tumor includes at least one of colorectal cancer, bladder cancer, breast cancer, cervical squamous cell carcinoma, pheochromocytoma, diffuse large B-cell lymphoma, esophageal cancer, glioblastoma, head and neck tumor, kidney cancer, acute myeloid leukemia, glioma, liver cancer, lung cancer, pancreatic cancer, nasopharyngeal carcinoma, kidney cancer, lung cancer, liver cancer, breast cancer, prostate cancer, gastrointestinal cancer, sarcomatoid lung cancer, gastric adenocarcinoma, thyroid cancer, and thymic carcinoma.

[0069] The beneficial effects of this invention are: This invention provides a fusion protein with tumor-targeting cell penetration and anti-tumor immune activation. This fusion protein can directly deliver the DDX60 functional domain into tumor cells and maintain dsRNA stability. Simultaneously, it can enhance the sensitivity to other anti-tumor immunotherapies by activating the body's own immunity. As a novel natural immune agonist, this fusion protein synergistically enhances anti-tumor immunity through a dual mechanism (HL60-mediated intracellular pathogen pattern recognition and Fc-mediated immune cell recruitment / activation), potentially overcoming drug resistance issues in existing ICB therapies for "cold tumors" such as colorectal cancer, pancreatic cancer, and lung cancer. It provides a new and effective strategy for tumor immunotherapy and has significant implications for cancer treatment.

[0070] Compared to small molecule drugs, the HL60-Fc fusion protein provided in this application is simple to synthesize and can be expressed in prokaryotic or eukaryotic systems, making it convenient to produce, highly effective, and easier to mass-produce and commercialize. Attached Figure Description

[0071] The present invention will be further described below with reference to the accompanying drawings and embodiments, wherein: Figure 1 This is a schematic diagram illustrating the construction of the HL60-Fc fusion protein.

[0072] Figure 2 This image shows the purification effect of the HL60-Fc fusion protein; the target fusion protein is shown within the box.

[0073] Figure 3 The figure shows the results of HL60-Fc fusion protein inhibiting tumor growth.

[0074] Figure 4 This is a flow cytometry plot of the HL60-Fc fusion protein therapeutic assay. represent p <0.05, represent p <0.001, represent p <0.0001.

[0075] Figure 5 The HL60-Fc fusion protein had no significant effect on mouse body weight.

[0076] Figure 6 Pathological analysis showed that the HL60-Fc fusion protein had no significant side effects on mice. The scale bar is 20 micrometers.

[0077] Figure 7 The purification effect of the fusion protein HL60-ABD is shown in the figure: the target fusion protein is inside the box.

[0078] Figure 8 To compare the tumor suppression effects of HL60-Fc and HL60-ABD and clarify the importance of the Fc segment in tumor suppression function. Detailed Implementation

[0079] The following will describe the concept and technical effects of the present invention clearly and completely with reference to embodiments, so as to fully understand the purpose, features and effects of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are all within the scope of protection of the present invention.

[0080] Unless otherwise specified in the examples, the procedures should be performed under standard conditions or conditions recommended by the manufacturer. Reagents or instruments whose manufacturers are not specified are all commercially available products.

[0081] The term "protein" is used interchangeably with "amino acid residue sequence" or "peptide" and refers to a polymer of amino acids of any length. These terms also include proteins that undergo post-translational modifications through reactions including, but not limited to, glycosylation, acetylation, phosphorylation, glycation, or protein processing. Modifications and alterations can be made to the structure of a peptide, such as fusion with other proteins, amino acid sequence substitution, deletion, or insertion, while the molecule retains its biological functional activity. For example, certain amino acid sequence substitutions can be made in a peptide or the nucleic acid-coding sequence of its basis, and proteins with the same properties can be obtained. The term "peptide" generally refers to a sequence having more than 10 amino acids, and the term "peptide" means a sequence having a length of up to 10 amino acids. However, these terms are used interchangeably.

[0082] The term "fusion protein" is defined as a protein containing the complete sequence or any portion of the sequence of two or more originally separate natural or modified heterologous proteins, or a composition of two or more originally separate natural or modified heterologous proteins. Fusion proteins can be constructed using genetic engineering methods by fusing two or more genes or portions thereof that originally encode two or more originally separate natural or heterologous proteins or portions thereof. This produces a fusion protein having functional properties derived from each original protein. Fusion proteins include, but are not limited to, Fc fusion proteins.

[0083] The term "gene" refers to a DNA locus in a heritable genomic sequence that influences an organism's traits by being expressed as a functional product or by regulating gene expression. Genes and polynucleotides may contain introns and exons, as in genomic sequences, or only coding sequences, as in cDNA, such as open reading frames (ORFs), which contain a start codon (methionine codon) and a translation stop codon. Genes and polynucleotides may also contain regions that regulate their expression, such as transcription initiation, translation, and transcription termination. Therefore, they also contain regulatory elements such as promoters.

[0084] The terms “enhancement,” “increase,” and “increase in elevation” are used interchangeably in this document and refer to an increase of at least about 10% compared to the control, such as an increase of at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 75%, at least about 80%, at least about 90%, at least about 100%, at least about 200%, or at least about 300%, or any integer reduction between 10% and 300% compared to the control.

[0085] The term "vector" refers to a nucleic acid that can be used to introduce heterologous polynucleotides into cells. One type of vector is the "plasmid," which is a linear or circular double-stranded DNA molecule in which additional nucleic acid segments can be linked. Another type of vector is a viral vector (such as replication-defective retroviruses, adenoviruses, and adeno-associated viruses), in which additional DNA or RNA segments can be introduced into the viral genome.

[0086] The term "encoding" broadly refers to any process that uses information within a polymer macromolecule to guide the production of a second molecule different from the first. In other respects, DNA molecules can encode RNA molecules (e.g., through transcription using DNA-dependent RNA polymerase). Furthermore, RNA molecules can encode polypeptides, as in translation. When used to describe the translation process, the term "encoding" is also extended to encoding triplet codons for amino acids. In some respects, RNA molecules can encode DNA molecules, for example, through reverse transcription incorporating RNA-dependent DNA polymerase. In other respects, DNA molecules can encode polypeptides, where it should be understood that the use of "encoding" in this case incorporates both transcription and translation.

[0087] The term "immune checkpoint inhibitory antibody" refers to an antibody as defined above that binds to an inhibitory receptor (IR) or more broadly interferes with the interaction between the inhibitory receptor and its ligand, wherein the inhibitory receptor is essential for balancing co-stimulatory receptor activity and limiting T cell activation. Therefore, such antibodies target immune system checkpoints such as cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death factor 1 (PD-1), or its ligand (PD-L1). Examples of immune checkpoint inhibitory antibodies suitable for use in this application are, but are not limited to, anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-IDO antibodies, anti-CTLA-4 antibodies, anti-Tim-3 antibodies, anti-GITR antibodies, anti-OX40 antibodies, or anti-LAG3 antibodies. Furthermore, anti-FGL1 antibodies can be considered immune checkpoint inhibitors. In most cases, immune checkpoint inhibitory antibodies are antagonistic or blocking antibodies, specifically, blocking antibodies selected from the following: anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-IDO antibodies, anti-CTLA-4 antibodies, anti-Tim-3 antibodies, anti-LAG3 antibodies, anti-VISTA antibodies, and anti-BTLA antibodies. However, immune checkpoint inhibitory antibodies can also be agonistic antibodies, such as anti-GITR or anti-OX40 antibodies. Regarding anti-LAG3 antibodies, these antibodies can be those that selectively inhibit the interaction of LAG3 with MHC class II molecules, selectively inhibit the interaction of LAG3 with FGL1, or inhibit the interaction of LAG3 with both FGL1 and MHC class II molecules.

[0088] The features and performance of the present invention will be further described in detail below with reference to embodiments.

[0089] Example 1: Construction and efficacy verification of the HL60-Fc fusion protein This embodiment uses the designed and constructed HL60-Fc fusion protein to induce anti-tumor immunity as an example to demonstrate and confirm the feasibility and advantages of the technical solution of this application. The DDX60 protein participates in maintaining dsRNA stability and activating anti-tumor immunity. Therefore, the designed drug can, on the one hand, bring the functional domain of the DDX60 protein into tumor cells to activate the anti-tumor immune response; on the other hand, by binding to and activating dendritic cells through the Fc segment of the fusion protein, it can further activate specific lymphocytes targeting the HL60 antigen, which is of great significance for the clinical treatment of tumors.

[0090] I. Preparation of HL60-Fc fusion protein molecules (I) Design and construction of HL60-Fc molecular tools

[0091] A schematic diagram of the construction of the HL60-Fc fusion protein is shown below. Figure 1 As shown.

[0092] (II) Expression and purification of HL60-Fc fusion protein 1. The HL60-Fc fusion protein was expressed using 293F cells. In this example, 293F cells needed to be prepared first. A 2 L Erlenmeyer flask was prepared, sealed with a ventilated membrane, and then autoclaved. Next, in the cell culture chamber, 1 L of DMEM culture medium, 50 mL of serum, and 10 mL of penicillin-streptomycin mixture were added to the flask. The working concentration of penicillin was 100 U / mL, and the working concentration of streptomycin was 100 μg / mL. The 293F cells cultured in the culture dish were taken, washed with PBS, and digested with 1 mL of trypsin for 1 minute. Then, 1 mL of DMEM was added to stop the digestion. The resulting cell suspension was transferred to a 5 mL centrifuge tube, centrifuged at 1000 rcf for 4 minutes, the supernatant was discarded, and 5 mL of DMEM culture medium was added and mixed thoroughly. The mixture was then transferred to the Erlenmeyer flask. Place the conical flask in a cell culture shaker and incubate overnight at 120 rpm, 5% CO2, and 37°C; measure the cell concentration the next day to achieve a cell density of 1×10⁻⁶. 8 Cells / mL. For final co-transfection, prepare two containers, each containing 30 mL of serum-free DMEM. Add 1 mg of HL60-Fc plasmid to one 30 mL DMEM container, and 6 mL of PEI to the other 30 mL DMEM container. Slowly mix the two containers thoroughly, let stand for 10 minutes, and then add the mixture to the 293F cells in the conical flask. Continue culturing under the same shaker conditions for 5-6 days. After culturing, centrifuge at 8000 g for 30 minutes, discard the precipitate, and filter the supernatant through 0.65 μm filter paper. The supernatant is used for subsequent purification.

[0093] 2. The supernatant obtained above was added to a column containing Ni-NTA agarose gel and filtered. The filtrate was filtered once more. During filtration, the Ni-NTA agarose gel changed from blue to white. 20 µL of the supernatant was collected for subsequent purification efficiency verification. The gel was then washed three times with 1×PBS buffer containing 20 mM imidazole, twice the column volume each time. 20 µL of the final wash was collected. Elution was then performed with 1×PBS buffer containing 300 mM imidazole. If the Ni-NTA agarose gel turned blue again, the elution was considered complete. 20 µL of the eluent was retained as a sample. The sample retained during the purification process was analyzed using 10% SDS-PAGE to determine the purification efficiency of the fusion protein. The eluent was centrifuged at 10,000 g for 10 min. The supernatant was concentrated into a fusion protein using a 30 kD ultrafiltration tube (Millipore, catalog number: UFC9030), centrifuged at 4500 g, and ultrafiltered to 500 μL at 4°C. The concentrate was then washed three times with 1×PBS, and centrifuged three times in total. The concentration of the obtained concentrated protein was determined using a BCA protein concentration assay kit (Thermo Fisher, catalog number: 23227) and stored at -80°C.

[0094] The purification effect of HL60-Fc fusion protein is as follows: Figure 2 As shown, the purity reached over 90%, which can be used for subsequent experimental verification.

[0095] The amino acid sequence of the HL60-Fc fusion protein is shown in SEQ ID NO:2: RAGLQFPVGRLLRRLLR GSG LDVVDKNESAVIVAPTSSGKTYASYYCMEKVLKESDDGVVVYVAPTKA LVNQVAATVQNRFTKNLPSGEVLCGVFTREYRHDALNCQVLITVPACFEILLLAPHRQNWVKKIRYVIFDEVHCLG GEIGAEIWEHLLVMIRCPFLALSATISNPEHLTEWLQSVKWYWKGSGGSGYADQKAVDTETLQKVFGRVKFERKGE ELKALAERGIGYHHSAMSFKEKQLVEILFRKGYLRVVTATGTLALGVNMPCKSVVFAQNSVYLDALNYRQMSGRAG RRGQDLMGDVYFFDIPFPKIGK GGGSSGG EPKSADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCV VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:2).

[0096] In this sequence, the single underlined portion is the amino acid sequence of BR2, a tumor-targeting cell-penetrating peptide, and is designated as SEQ ID NO:3; the bolded portion is the flexible link sequence between the functional regions, where GSGGSG is designated as SEQ ID NO:4 and GGGSSGG as SEQ ID NO:5; the double underlined portion is the DDX60 functional domain (including the ATP-binding and hydrolysis domain and the RNA-binding domain, whose amino acid sequences are shown in SEQ ID NO:7 and SEQ ID NO:8, respectively), and its amino acid sequence is designated as SEQ ID NO:6; the italicized portion is the Fc fragment, and its amino acid sequence is designated as SEQ ID NO:9.

[0097] LDVVDKNESAVIVAPTSSGKTYASYYCMEKVLKESDDGVVVYVAPTKALVNQVAATVQNRFTKNLPSGEVLCGVFTREYRHDALNCQVLITVPACFEILLLAPHRQNWVKKIRYVIFDEVHCLGGEIWEHLLVMIRCPFLALSATISNPEHLTEWLQSVKWYWK (SEQ ID NO: 7).

[0098] YADQKAVDTETLQKVFGRVKFERKGEELKALAERGIGYHHSAMSFKEKQLVEILFRKGYLRVVTATGTLALGVNMPCKSVVFAQNSVYLDALNYRQMSGRAGRRGQDLMGDVYFFDIPFPKIGK (SEQ ID NO: 8).

[0099] II. Verification of the effect of HL60-Fc fusion protein in inhibiting tumor growth C57BL / 6J mice (4-8 weeks old) were used in all experiments and purchased from the Guangdong Provincial Animal Experiment Center. All animal experiments were approved by the Animal Ethics Committee of Sun Yat-sen University (Approval No. L025501202407004). Mice were randomly divided into groups of 6. On day 0, mice were injected into both sides of their backs with 5 × 10⁻⁶ KRAS-overexpressing murine colorectal cancer cells MC38 (MC38K). 5 One week after tumor inoculation, intraperitoneal injections were initiated, with the following groups: (1) phosphate-buffered saline solution; (2) HL60-Fc fusion protein (200 µg); (3) fusion protein HL60 (200 µg). The only difference between fusion protein HL60 and HL60-Fc fusion protein is that HL60 does not contain the Fc fragment.

[0100] Inject once every 3 days for 3 consecutive weeks. Inject when tumor necrosis occurs or the tumor volume reaches 1500 mm. 3 Mice were sacrificed at the designated time, and the endpoint of death was recorded. Tumor size was measured every three days using calipers, with the length (L) and width (W) measured separately and then calculated according to the formula Volume (mm). 3 =LW 2The tumor volume was calculated using a ratio of 2 / 2. C57 mice were weighed every three days using an electronic balance, for a total of seven measurements. The first measurement served as the control group, while subsequent measurements after intraperitoneal injection served as the experimental group. Tumor growth volumes were calculated, and growth curves were plotted. At the end of the experiment, tumors from three mice each from the phosphate-buffered saline control group, the HL60-Fc fusion protein group, and the HL60 fusion protein group were analyzed by flow cytometry to assess the infiltration of immune cells within the tumors.

[0101] The results showed that, compared with the phosphate-buffered saline solution group, treatment with the HL60-Fc fusion protein significantly inhibited tumor growth, and its antitumor effect was significantly better than that of the HL60 fusion protein group. Figure 3 This indicates that the HL60-Fc fusion protein has a significant anti-tumor effect. Simultaneously, flow cytometry analysis showed increased CD4 and CD8 cell infiltration within tumors after treatment with the HL60-Fc fusion protein, suggesting that the HL60-Fc fusion protein can promote the body's anti-tumor immune response. Figure 4 This suggests that the HL60-Fc fusion protein can enhance the sensitivity to immune checkpoint inhibitors.

[0102] III. In vivo safety verification of HL60-Fc fusion protein This experiment aimed to evaluate the safety of the HL60-Fc fusion protein in mice. C57BL / 6J mice (4-8 weeks old) were used in the experiment, and all animal experiments were approved by the Animal Ethics Committee of Sun Yat-sen University. Mice were administered the HL60-Fc fusion protein intraperitoneally at a dose of 100 mg / kg. Physiological and mental status changes in the mice were recorded in detail within 80 hours after administration, and their body weight was measured regularly. A comprehensive pathological analysis of their internal organs was performed at the end of the experiment.

[0103] The results showed that after injection of HL60-Fc fusion protein, the mice maintained normal mental state during the observation period after administration, and the mouse body weight did not show significant changes. Figure 5 ); Pathological examination of the major internal organs of the mice showed no obvious tissue damage or pathological changes. Figure 6 The experimental results indicate that the HL60-Fc fusion protein has good safety at a set dose of 100 mg.

[0104] Example 2: Validation of the efficacy of the fusion protein HL60-ABD Example 1 illustrates the design concept of the HL60-Fc fusion protein and verifies its role in activating anti-tumor immunity and inhibiting tumor growth. To further clarify the indispensability of the Fc fragment in the fusion protein, this example uses the albumin-binding region (ABD) instead of the Fc fragment to construct the fusion protein HL60-ABD and evaluates its tumor-suppressive effect.

[0105] I. Preparation of the fusion protein HL60-ABD (I) Design and construction of HL60-ABD molecular tools

[0106] (II) Expression and purification of fusion protein HL60-ABD 1. The fusion protein HL60-ABD was expressed using 293F cells. In this example, 293F cells needed to be prepared first. A 2 L Erlenmeyer flask was prepared, sealed with a ventilated membrane, and autoclaved. Then, in the cell culture room, 1 L of DMEM culture medium, 50 mL of serum, and 10 mL of penicillin-streptomycin mixture were added to the flask. The working concentration of penicillin was 100 U / mL, and the working concentration of streptomycin was 100 μg / mL. The 293F cells cultured in the culture dish were taken, washed with PBS, and digested with 1 mL of trypsin for 1 minute. Then, 1 mL of DMEM was added to stop the digestion. The resulting cell suspension was transferred to a 5 mL centrifuge tube, centrifuged at 1000 rcf for 4 minutes, the supernatant was discarded, 5 mL of DMEM culture medium was added, and the mixture was mixed thoroughly and transferred to the Erlenmeyer flask. Place the conical flask in a cell culture shaker and incubate overnight at 120 rpm, 5% CO2, and 37°C; measure the cell concentration the next day to achieve a cell density of 1×10⁻⁶. 6 Cells / mL. For final co-transfection, prepare two containers, each containing 30 mL of serum-free DMEM. Add 1 mg of HL60-ABD plasmid to one 30 mL DMEM container, and 6 mL of PEI to the other 30 mL DMEM container. Slowly mix the two containers thoroughly, let stand for 10 minutes, and then add the mixture to the 293F cells in the conical flask. Continue culturing under the same shaker conditions for 5-6 days. After culturing, centrifuge at 8000 g for 30 minutes, discard the precipitate, and filter the supernatant through 0.65 μm filter paper. The supernatant is used for subsequent purification.

[0107] 2. The supernatant obtained above was added to a column containing Ni-NTA agarose gel and filtered. The filtrate was filtered once more. During filtration, the Ni-NTA agarose gel changed from blue to white. 20 µL of the supernatant was collected for subsequent purification efficiency verification. The gel was then washed three times with 1×PBS buffer containing 20 mM imidazole, twice the column volume each time. 20 µL of the final wash was collected. Elution was then performed with 1×PBS buffer containing 300 mM imidazole. If the Ni-NTA agarose gel turned blue again, the elution was considered complete. 20 µL of the eluent was retained as a sample. The sample retained during the purification process was analyzed using 10% SDS-PAGE to determine the purification efficiency of the fusion protein. The eluent was centrifuged at 10,000 g for 10 min. The supernatant was concentrated into a fusion protein using a 30 kD ultrafiltration tube (Millipore, catalog number: UFC9030), centrifuged at 4500 g, and ultrafiltered to 500 μL at 4°C. The concentrate was then washed three times with 1×PBS, and centrifuged three times in total. The concentration of the obtained concentrated protein was determined using a BCA protein concentration assay kit (Thermo Fisher, catalog number: 23227) and stored at -80°C.

[0108] The purification effect of the fusion protein HL60-ABD is as follows: Figure 7 As shown, the purity reached over 90%, which can be used for subsequent experimental verification.

[0109] The amino acid sequence of the fusion protein HL60-ABD is as follows: RAGLQFPVGRLLRRLLR GSGLDVVDKNESAVIVAPTSSGKTYASYYCMEKVLKESDDGVVVYVAPTKALVNQVAATVQNRFTKNLPSGEVLCGVFTREYRHDALNCQVLITVPACFEILLLAPHRQNWVKKIRYVIFDEVHCLGGEIGAEIWEHLLVMIRCPFLALSATI SNPEHLTEWLQSVKWYWKGSGGSGYADQKAVDTETLQKVFGRVKFERKGEELKALAERGIGYHHSAMSFKEKQLVEILFRKGYLRVVTATGTLALGVNMPCKSVVFAQNSVYLDALNYRQMSGRAGRRGQDLMGDVYFFDIPFPKIGKGSGSSG LAEAKVLANRELDKYGVSDFYKRLINKAKTVEGVEALKLHILAALP (SEQ ID NO:11).

[0110] In this sequence, the single underline represents the amino acid sequence of BR2, a tumor-targeting cell-penetrating peptide; the bolded portion represents the flexible linking sequence between the functional regions; and the double underlined portion represents the albumin-binding region (ABD), whose amino acid sequence is SEQ ID NO:12.

[0111] II. Verification of the effect of HL60-ABD fusion protein in inhibiting tumor growth C57BL / 6J mice (4-8 weeks old) were used in all experiments and purchased from the Guangdong Provincial Animal Experiment Center. All animal experiments were approved by the Animal Ethics Committee of Sun Yat-sen University (Approval No. L025501202407004). Mice were randomly divided into groups of 6. On day 0, mice were injected into both sides of their backs with 5 × 10⁻⁶ KRAS-overexpressing murine colorectal cancer cells MC38 (MC38K). 5 One week after tumor inoculation, intraperitoneal injection was initiated, with the following groups: (1) phosphate buffered saline solution; (2) HL60-Fc fusion protein (200 µg); (3) fusion protein HL60-ABD (200 µg).

[0112] Inject once every 3 days for 3 consecutive weeks. Inject when tumor necrosis occurs or the tumor volume reaches 1500 mm. 3 Mice were sacrificed at the designated time, and the endpoint of death was recorded. Tumor size was measured every three days using calipers, with the length (L) and width (W) measured separately and then calculated according to the formula Volume (mm). 3 =LW 2 The tumor volume was calculated using a ratio of 2 / 2. The weight of C57 mice was measured every three days using an electronic balance, for a total of 7 measurements. The tumor volume of each group of C57 mice was divided into two groups: the first measurement served as the control group, and the measurements after intraperitoneal injection served as the experimental group. The tumor growth volume was calculated and growth curves were plotted.

[0113] The results showed that, compared with the phosphate-buffered saline solution group, treatment with the HL60-Fc fusion protein also significantly inhibited tumor growth, and its antitumor effect was significantly better than that of the HL60-ABD fusion protein group. Figure 8 This indicates that the Fc fragment is irreplaceable in the antitumor effect of the fusion protein.

[0114] The embodiments of the present invention have been described in detail above with reference to the accompanying drawings. However, the present invention is not limited to the above embodiments, and various changes can be made within the scope of knowledge possessed by those skilled in the art without departing from the spirit of the present invention. Furthermore, the embodiments of the present invention and the features thereof can be combined with each other unless otherwise specified.

Claims

1. A fusion protein, characterized in that, The fusion protein includes a tumor-targeting cell-penetrating peptide, a DDX60 functional domain, and an Fc fragment of an IgG antibody. The nucleotide sequence of the Fc fragment is as shown in SEQ ID NO:9, or the amino acid sequence shown in SEQ ID NO:9 after substitution, deletion or addition of one or more amino acids and with the same or similar function.

2. The fusion protein of claim 1, wherein, The tumor-targeting cell-penetrating peptides include BR2; Preferably, the amino acid sequence of the tumor-targeting cell-penetrating peptide is as shown in SEQ ID NO:3, or the amino acid sequence shown in SEQ ID NO:3 is modified by substitution, deletion or addition of one or more amino acids and has the same or similar function.

3. The fusion protein of claim 1, wherein, The DDX60 functional domains include an ATP-binding and hydrolysis domain and an RNA-binding domain, which are connected by a flexible linker. Preferably, the amino acid sequence of the ATP-binding and hydrolysis domains is any one of a1) to a3): a1) As shown in SEQ ID NO:7; a2) SEQ ID NO:7 is an amino acid sequence that has undergone substitution and / or deletion and / or addition of one or more amino acids and has the same or similar function; a3) An amino acid sequence that has 99%, 98%, 97%, 96%, 95%, 94%, 93% or 92% homology with SEQ ID NO:7 and has the same function as SEQ ID NO:7; Preferably, the amino acid sequence of the RNA-binding domain is any one of b1) to b3): b1) As shown in SEQ ID NO:8; b2) The amino acid sequence of SEQ ID NO:8 that has undergone substitution and / or deletion and / or addition of one or more amino acids and has the same or similar function; b3) An amino acid sequence that has 99%, 98%, 97%, 96%, 95%, 94%, 93% or 92% homology with SEQ ID NO:8 and has the same function as SEQ ID NO:8; Preferably, the ATP binding and hydrolysis domain is located at the N-terminus or C-terminus of the RNA binding domain.

4. The fusion protein according to any one of claims 1-3, characterized in that, The tumor-targeting cell-penetrating peptide, DDX60 functional domain, and Fc fragment are linked by a flexible linker. Preferably, the amino acid sequence of the flexible linker is (GGCAGCGCCAGC) n , (GGCGGCGGCAGC) n , (GGCGGCGGCGGCAGC) n , YAPVDV, (GGGS) n , (GGSG) n , (GSG) n , GGGSSGG, (GGGGS) n wherein 1n10 and n is an integer; Preferably, the DDX60 functional domain is located at the N-terminus or C-terminus of the tumor-targeting cell-penetrating peptide; Preferably, the Fc segment is located at the N-terminus or C-terminus of the DDX60 functional structure domain.

5. The fusion protein according to claim 4, characterized in that, The amino acid sequence of the fusion protein is shown in SEQ ID NO:2; or the amino acid sequence shown in SEQ ID NO:2 modified by substitution, deletion or addition of one or more amino acids, and has the same or similar function.

6. A biomaterial relating to the fusion protein of any one of claims 1-5, characterized in that, The biomaterial is any one of c1) to c12): c1) A nucleic acid molecule encoding the fusion protein according to any one of claims 1-5; c2) An expression cassette containing the nucleic acid molecule described in c1); c3) A recombinant vector containing the nucleic acid molecule described in c1); c4) A recombinant vector containing the expression cassette described in c2); c5) Recombinant microorganisms containing the nucleic acid molecules described in c1); c6) Recombinant microorganisms containing the expression cassette described in c2); c7) Recombinant microorganisms containing the recombinant vector described in c3); c8) Recombinant microorganisms containing the recombinant vector described in c4); c9) Transgenic animal cell lines containing the nucleic acid molecules described in c1); c10) Transgenic animal cell lines containing the expression cassette described in c2); c11) Transgenic animal cell lines containing the recombinant vector described in c3); c12) Transgenic animal cell lines containing the recombinant vector described in c4); The transgenic animal cell lines do not contain reproductive material.

7. The use of the fusion protein of any one of claims 1-5 or the biomaterial of claim 6 in any one of d1)-d3): d1) Prepare drugs for the prevention and / or treatment of tumors; d2) Preparation of drugs that activate anti-tumor immunity; d3) Prepare drugs that enhance the anti-tumor effects of immune checkpoint inhibitors.

8. The application according to claim 7, characterized in that, The tumors include at least one of the following: colorectal cancer, bladder cancer, breast cancer, cervical squamous cell carcinoma, pheochromocytoma, diffuse large B-cell lymphoma, esophageal cancer, glioblastoma, head and neck tumors, kidney cancer, acute myeloid leukemia, glioma, liver cancer, lung cancer, pancreatic cancer, nasopharyngeal carcinoma, kidney cancer, lung cancer, liver cancer, breast cancer, prostate cancer, gastrointestinal cancer, sarcomatoid lung cancer, gastric adenocarcinoma, thyroid cancer, and thymic carcinoma.

9. A drug, characterized in that, The drug comprises the fusion protein of any one of claims 1-5 or the biomaterial of claim 6.

10. The medicament according to claim 9, characterized in that, The drugs also include combination drugs; Preferably, the combination drugs include tumor-targeting drugs.